Who Paid My Doc
Lachin Hatemi
General Practice Lexington, SC Medical Doctor
NPI 1316265515 CMS profile 2791061
247 Columbia Ave, Lexington, SC 29072
General payments
$627
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$6,700
Through program year 2025, Lachin Hatemi of Lexington, SC is reported in the CMS Open Payments database as having received $627 across 20 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $6,700 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 72nd percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $69 | 2 | |
| 2024 | General | $162 | 2 | |
| 2023 | General | $200 | 4 | |
| 2022 | General | $79 | 4 | |
| 2021 | General | $25 | 2 | |
| 2020 | General | $81 | 5 | |
| 2019 | General | $13 | 1 |
Beside peers
- Lachin Hatemi
- General Practice median
- Middle half of General Practice
- National median
In program year 2025, general payments to Lachin Hatemi were reported at $69. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.
Show as a table
| Year | Lachin Hatemi | General Practice median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $13 | $107 | $37–$285 | $163 |
| 2020 | $81 | $75 | $25–$213 | $114 |
| 2021 | $25 | $93 | $30–$272 | $132 |
| 2022 | $79 | $103 | $36–$279 | $149 |
| 2023 | $200 | $106 | $34–$276 | $160 |
| 2024 | $162 | $114 | $39–$290 | $164 |
| 2025 | $69 | $106 | $35–$292 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 45 drugsPart D claims
1,485
Drug cost
$76,771
Branded share of claims
23.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Mounjaro Tirzepatide | Brand | 38 | $40,305 | |
| Ozempic Semaglutide | Brand | 18 | $17,071 | |
| Eliquis Apixaban | Brand | 16 | $9,533 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 40 | $1,310 | |
| Clindamycin Hcl | Generic | 165 | $1,235 | |
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | Brand | 24 | $890 | |
| Ipratropium Bromide | Generic | 26 | $570 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 39 | $431 | |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | Brand | 53 | $394 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 69 | $355 |
The 10 drugs with the highest cost, of 45 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.
Billing to Medicare
Part B · data year 2024 · 60 billing codesPaid by Medicare
$60,275
Medicare patients
315
Services billed
3,952
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 71% | |
| Arthritis | 52% | |
| Ischemic heart disease | 29% | |
| Diabetes | 21% | |
| Depression | 20% | |
| Chronic kidney disease | 18% | |
| Cancer | 16% | |
| Atrial fibrillation | 14% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, ketorolac tromethamine, per 15 mg J1885 | Office | 79 | 397 | $210 |
| Injection, nalbuphine hydrochloride, per 10 mg J2300 | Office | 33 | 70 | $166 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 | Office | 80 | 123 | $114 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 101 | 1,332 | $113 |
| Injection, ceftriaxone sodium, per 250 mg J0696 | Office | 51 | 288 | $98 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg J7611 | Office | 32 | 119 | $15 |
| Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram J7644 | Office | 33 | 41 | $11 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
20 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
General Practice in South Carolina
Practitioners in the same specialty and state, ranked by reported value.
All General Practice
Everyone recorded under this specialty, nationwide.
Doctors in South Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.